You just read:

Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

News provided by

MEI Pharma, Inc.

Aug 02, 2017, 08:00 ET